ACAD (STOCKS)
Acadia Pharmaceuticals Inc.
$21.650000
-0.090000 (-0.41%)
Prev close: $21.740000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Catherine Owen Adams
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,657.12M
- Employees
- 654
- P/E (TTM)
- 9.45
- P/B (TTM)
- 3.02
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
14
Buy
5
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$1.60 | $0.14 | +1.4602 | +1,044.49% |
|
Sep 2025 (Q3)
|
$0.42 | $0.15 | +0.2690 | +178.15% |
|
Jun 2025 (Q2)
|
$0.16 | $0.14 | +0.0202 | +14.45% |
|
Mar 2025 (Q1)
|
$0.11 | $0.11 | -0.0036 | -3.17% |
Financial Statements
| Revenues | $1.07B |
| Benefits Costs and Expenses | $932.60M |
| Cost Of Revenue | $89.00M |
| Costs And Expenses | $966.69M |
| Gross Profit | $982.51M |
| Operating Expenses | $877.70M |
| Selling, General, and Administrative Expenses | $548.89M |
| Research and Development | $328.80M |
| Operating Income/Loss | $104.81M |
| Income/Loss Before Equity Method Investments | $0.00 |
| Income/Loss From Continuing Operations After Tax | $391.00M |
| Income/Loss From Continuing Operations Before Tax | $138.90M |
| Income/Loss From Equity Method Investments | $138.90M |
| Income Tax Expense/Benefit | -$252.10M |
| Income Tax Expense/Benefit, Current | -$1.77M |
| Income Tax Expense/Benefit, Deferred | -$250.32M |
| Net Income/Loss | $391.00M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $391.00M |
| Net Income/Loss Available To Common Stockholders, Basic | $391.00M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.32 |
| Diluted Earnings Per Share | $2.30 |
| Basic Average Shares | 168,356,000 |
| Diluted Average Shares | 169,919,000 |
| Assets | $1.56B |
| Current Assets | $1.06B |
| Inventory | $111.37M |
| Prepaid Expenses | $59.53M |
| Other Current Assets | $891.21M |
| Noncurrent Assets | $502.08M |
| Fixed Assets | $7.51M |
| Other Non-current Assets | $494.57M |
| Liabilities | $336.81M |
| Current Liabilities | $277.11M |
| Accounts Payable | $10.90M |
| Wages | $45.58M |
| Other Current Liabilities | $220.63M |
| Noncurrent Liabilities | $59.69M |
| Equity | $1.23B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.23B |
| Liabilities And Equity | $1.56B |
| Net Cash Flow From Operating Activities | $109.84M |
| Net Cash Flow From Operating Activities, Continuing | $109.84M |
| Net Cash Flow From Investing Activities | -$302.56M |
| Net Cash Flow From Investing Activities, Continuing | -$302.56M |
| Net Cash Flow From Financing Activities | $49.88M |
| Net Cash Flow From Financing Activities, Continuing | $49.88M |
| Net Cash Flow | -$142.85M |
| Net Cash Flow, Continuing | -$142.85M |
| Comprehensive Income/Loss | $392.15M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $392.15M |
| Other Comprehensive Income/Loss | $1.15M |